Clinical trials: Non-small Cell Lung Cancer Patients
Metastatic Non-Small Cell Lung Cancer
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer
The purpose of this expanded access program (EAP) is to provide amivantamab for the treatment of participants with metastatic non-small cell lung cancer who have epidermal growth factor receptor exon 20 insertion mutations, and…
- Trial name
- NCT04599712
- Testing
- Amivantamab
- Sponsor
- Janssen Research & Development, LLC
Solid Tumor
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal…
- Trial name
- MasterKey-01 (NCT04209465)
- Testing
- BDTX-189
- Where
- 38 sites in United States, Denmark and 2 more
- Volunteers
- 91 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Non-Small Cell Lung Cancer
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada
This study uses existing medical records to better understand how immunotherapy is used in people in Europe and Canada with non-small cell lung cancer (NSCLC) who undergo surgery.
- Trial name
- NCT07718139
- Testing
- nivolumab, pembrolizumab, durvalumab
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.
- Trial name
- NCT06114511
- Testing
- BL-M07D1
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Carcinoma, Non-small Cell Lung Cancer
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
The purpose of the study was to determine whether the combination of aflibercept, pemetrexed and cisplatin is safe and effective in treating non-small cell lung cancer (NSCLC).
- Trial name
- NCT00794417
- Testing
- Aflibercept, Pemetrexed, Cisplatin
- Where
- 15 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer
This is a Phase 2 study of oral dacomitinib given every 12 hours over days 1-4 of each two-week cycle to patients with Non-small cell lung cancer.
- Trial name
- NCT01858389
- Testing
- Dacomitinib
- Where
- 14 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Pfizer
Advanced Squamous Non-Small Cell Lung Carcinoma
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
RBN-2397 inhibits PARP7, an enzyme that is switched on by cancer stresses, such as the toxins in cigarette smoke. Cancer cells use PARP7 to hide from the immune system by stopping the cell from sending a signal (Type 1…
- Trial name
- NCT05127590
- Testing
- RBN-2397
- Where
- 19 sites in United States, Israel and 2 more
- Volunteers
- 50 people
- Sponsor
- Ribon Therapeutics, Inc.
Non Small Cell Lung Cancer, Solid Tumor
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M24D1 in patients with locally advanced or metastatic…
- Trial name
- NCT07232420
- Testing
- BL-M24D1
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva or placebo, plus platinum-based therapy, as first line treatment in patients with advanced or recurrent non-small cell lung cancer.
- Trial name
- NCT00883779
- Testing
- Platinum chemotherapy (cisplatin or carboplatin), erlotinib [Tarceva], gemcitabine
- Where
- 26 sites in China, Hong Kong and 5 more
- Volunteers
- 451 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced or Metastatic NSCLC
A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
HS-10504 is a fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR C797S mutation.
- Trial name
- NCT06461156
- Testing
- HS-10504
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
The aim of the study to evaluate the safety and efficacy of Sacituzumab Tirumotecan in combination with osimertinib for neoadjuvant treatment in patients with resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small…
- Trial name
- NCT07329322
- Testing
- Sacituzumab Tirumotecan, Osimertinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer (NSCLC)
A Study To Monitor Lung Cancer Patients Activity And Assess Performance Status Through A Wearable Device.
The current research is a non-interventional (NIS) study seeking to support objective Performance Status (PS) assessments in the particular context of metastatic NSCLC adult patients. To do so, the study comprises two phases.
- Trial name
- Lupa-01 (NCT04751162)
- Testing
- Actigraphy device (wearable) and mobile application
- Where
- 10 sites in Spain
- Volunteers
- 71 people
- Sponsor
- Hoffmann-La Roche
Lung Neoplasms, Carcinoma, Non-small Cell Lung
Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
This is a Phase 2 study being conducted at multiple centers in the United States and Germany. Patients having non-small cell lung cancer that has spread to other parts of the body (i.e., metastatic) or is locally advanced (i.e.…
- Trial name
- NCT00094094
- Testing
- axitinib
- Where
- 11 sites in United States, Germany
- Volunteers
- 32 people
- Sponsor
- Pfizer
Carcinoma, Non-Small Cell Lung
CPG 7909 Injection in Non-Small Cell Lung Cancer
Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone.
- Trial name
- NCT00070629
- Testing
- CPG 7909, Chemotherapy
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 116 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
This open-label, single-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer who have completed 4 cycles of standard platinum-based…
- Trial name
- NCT01230710
- Testing
- Erlotinib
- Where
- 7 sites in India
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
The aim of the study is to evaluate the efficacy and safety of SKB264 in combination with osimertinib as first-Line treatment for patients with epidermal growth factor receptor (EGFR) mutations, locally advanced or metastatic…
- Trial name
- NCT06670196
- Testing
- SKB264, Osimertinib
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
A Study to Assess the Efficacy and Safety of ABTL0812
A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC.
- Trial name
- Endolung (NCT03366480)
- Testing
- ABTL0812 in combination with paclitaxel and carboplatin
- Where
- Spain
- Volunteers
- 103 people
- Sponsor
- Ability Pharmaceuticals SL
Lung Cancer, Non-squamous, Non-small Cell
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including…
- Trial name
- NCT06151574
- Testing
- zongertinib, pembrolizumab, cisplatin
- Where
- 163 sites in United States, Argentina and 24 more
- Volunteers
- 428 people
- Sponsor
- Boehringer Ingelheim
Locally Advanced or Metastatic Solid Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1.
- Trial name
- NCT05194982
- Testing
- BL-B01D1
- Where
- 8 sites in China
- Volunteers
- 570 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Non Small Cell Lung Carcinoma NSCLC
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal…
- Trial name
- NCT03003962
- Testing
- Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin
- Where
- 92 sites in United States, Australia and 10 more
- Volunteers
- 669 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.